AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28581304 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal religiosity
Number of subjects: 193
Study 28581304 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms
Number of subjects: 193
Study 28581396 — intervention group
Group type: EXPERIMENTAL
Intervention: F-18 fluorodeoxyglucose (FDG) PET during chemoradiation therapy (CRT)
Number of subjects: 0
Study 28581691 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor XIII-A (rFXIII) prophylaxis, 35 IU/kg once monthly
Number of subjects: 6
Study 28582238 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart insole prototype
Number of subjects: 3
Study 28582240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based application (EPIC Wheels) with two in-person sessions and four weeks of independent home training
Number of subjects: 2
Study 28582240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based application (EPIC Wheels) with expert trainer monitoring
Number of subjects: 2
Study 28582240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based application (EPIC Wheels) with video instruction and interactive training games
Number of subjects: 2
Study 28582240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based application (EPIC Wheels) with standardized configuration for Wi-Fi devices
Number of subjects: 2
Study 28582240 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated EPIC Wheels software based on pilot results
Number of subjects: 2
Study 28582256 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based, algorithm-driven system (arm 3)
Number of subjects: 860
Study 28582256 — intervention group
Group type: EXPERIMENTAL
Intervention: Video version of static handout (arm 2)
Number of subjects: 860
Study 28582256 — intervention group
Group type: EXPERIMENTAL
Intervention: Static handout of exercises (arm 1)
Number of subjects: 860
Study 28582256 — intervention group
Group type: COMPARATOR
Intervention: All arms (1, 2, and 3)
Number of subjects: 860
Study 28582256 — intervention group
Group type: COMPARATOR
Intervention: Overall completion rates
Number of subjects: 860
Study 28582580 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3
Number of subjects: 301
Study 28582580 — intervention group
Group type: COMPARATOR
Intervention: SAPIEN XT
Number of subjects: 301
Study 28583131 — intervention group
Group type: EXPERIMENTAL
Intervention: Store features with health promoting characteristics (e.g., fruit/vegetable shelf space, Healthy Food Supply Score)
Number of subjects: 594
Study 28583131 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering ≥14 varieties of fruit/vegetables
Number of subjects: 594
Study 28583131 — intervention group
Group type: EXPERIMENTAL
Intervention: Produce visible from the store entrance
Number of subjects: 594
Study 28583131 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain availability measures
Number of subjects: 594
Study 28583262 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Spanish criteria
Number of subjects: 301
Study 28583262 — intervention group
Group type: EXPERIMENTAL
Intervention: ATS Roundtable criteria
Number of subjects: 301
Study 28583262 — intervention group
Group type: EXPERIMENTAL
Intervention: PLATINO criteria
Number of subjects: 301
Study 28583262 — intervention group
Group type: EXPERIMENTAL
Intervention: GINA/GOLD criteria
Number of subjects: 301
Study 28583305 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP5-IPV-HB-Hib vaccine administered at 2 and 6 months of age, DTaP5-IPV-Hib at 4 months, MCC vaccine at 2 and 4 months, and routine rotavirus and pneumococcal vaccination.
Number of subjects: 385
Study 28583305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed schedule including DTaP5-IPV-HB-Hib and MCC vaccine.
Number of subjects: 385
Study 28583305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed schedule with hexavalent vaccine and MCC vaccine.
Number of subjects: 385
Study 28583305 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine co-administered with MCC vaccine.
Number of subjects: 385
Study 28583305 — intervention group
Group type: EXPERIMENTAL
Intervention: Study vaccine doses.
Number of subjects: 385
Study 28583617 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable IV infusion system for treprostinil
Number of subjects: 64
Study 28583826 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR)
Number of subjects: 2106
Study 28584140 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS3123 (Methionyl-tRNA Synthetase Inhibitor)
Number of subjects: 0
Study 28584142 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin treatment
Number of subjects: 10
Study 28584252 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA plus anthracycline-based regimens (LPA2005 trial)
Number of subjects: 268
Study 28584252 — intervention group
Group type: COMPARATOR
Intervention: Non-age-adapted schedules (LPA96&LPA99 trials)
Number of subjects: 268
Study 28586789 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive SWOG treatment trials
Number of subjects: 12361
Study 28586923 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation metagenomic sequencing (NGMS)
Number of subjects: 156
Study 28586923 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative PCR assay for HHpgV-1
Number of subjects: 156
Study 28586923 — intervention group
Group type: EXPERIMENTAL
Intervention: NGMS
Number of subjects: 156
Study 28586923 — intervention group
Group type: EXPERIMENTAL
Intervention: HHpgV-1 viremia
Number of subjects: 156
Study 28587613 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4a
Number of subjects: 625
Study 28587667 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 652
Study 28587667 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 652
Study 28587667 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin peglispro (BIL) and insulin glargine
Number of subjects: 652
Study 28588018 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical HSCT after αβ T-cell and B-cell depletion
Number of subjects: 80
Study 28588020 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib
Number of subjects: 0
Study 28588020 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28588383 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Respiratory Insufficiency (SRI) Questionnaire
Number of subjects: 56
Study 28588383 — intervention group
Group type: EXPERIMENTAL
Intervention: Maugeri Respiratory Failure (MRF) Questionnaire
Number of subjects: 56
Study 28588383 — intervention group
Group type: EXPERIMENTAL
Intervention: St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 56
Study 28588421 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel product containing glycolic acid, sodium bicarbonate, glycerin, and other buffering agents, applied once before irrigation with warm water
Number of subjects: 30
Study 28588421 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel product with irrigation instructions followed
Number of subjects: 30
Study 28588421 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel product application
Number of subjects: 30
Study 28588421 — intervention group
Group type: EXPERIMENTAL
Intervention: Application satisfaction assessment
Number of subjects: 30
Study 28588426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramadan fasting (RF) with clopidogrel at a maintenance dose of 75 mg
Number of subjects: 98
Study 28588426 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel at a maintenance dose of 75 mg without Ramadan fasting
Number of subjects: 98
Study 28588946 — intervention group
Group type: EXPERIMENTAL
Intervention: Free RDT
Number of subjects: 444
Study 28588946 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy
Number of subjects: 444
Study 28588946 — intervention group
Group type: COMPARATOR
Intervention: No testing (control)
Number of subjects: 444
Study 28588946 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy with free RDT
Number of subjects: 444
Study 28588962 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based early childhood intervention package
Number of subjects: 526
Study 28588962 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 526
Study 28588982 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF-L
Number of subjects: 906
Study 28588982 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF-C
Number of subjects: 906
Study 28588982 — intervention group
Group type: COMPARATOR
Intervention: A-HPF
Number of subjects: 906
Study 28588992 — intervention group
Group type: EXPERIMENTAL
Intervention: mRDTs (malaria rapid diagnostic tests) introduced in drug shops
Number of subjects: 0
Study 28589002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigs for Peace (PFP) intervention
Number of subjects: 833
Study 28588977 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery in low-HDI countries
Number of subjects: 1409
Study 28588977 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery in middle-HDI countries
Number of subjects: 1409
Study 28588977 — intervention group
Group type: COMPARATOR
Intervention: High-HDI countries
Number of subjects: 1409
Study 28589492 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2874455 at 16 mg BID (RP2D)
Number of subjects: 36
Study 28590109 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free dish availability in food locals
Number of subjects: 112
Study 28590109 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate elaboration of gluten-free dishes
Number of subjects: 112
Study 28590109 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate food storage
Number of subjects: 112
Study 28590109 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate distribution of gluten-free dishes
Number of subjects: 112
Study 28590796 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging-guided high-intensity focused ultrasound (HIFU)
Number of subjects: 45
Study 28591336 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivisceral en bloc resection
Number of subjects: 105
Study 28591824 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kV with standard iterative reconstruction (IR)
Number of subjects: 14
Study 28591824 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kV with standard IR
Number of subjects: 14
Study 28591824 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kV with strong IR
Number of subjects: 14
Study 28591824 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kV protocols
Number of subjects: 14
Study 28591824 — intervention group
Group type: COMPARATOR
Intervention: 120 kV with standard IR (reference)
Number of subjects: 14
Study 28591824 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kV with standard IR
Number of subjects: 14
Study 28592230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin for CS-GNB patients
Number of subjects: 510
Study 28592230 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed prophylaxis for CR-GNB patients
Number of subjects: 510
Study 28592237 — intervention group
Group type: EXPERIMENTAL
Intervention: PartoMa guidelines
Number of subjects: 84
Study 28592289 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive weight-for-length at enrolment
Number of subjects: 642
Study 28592289 — intervention group
Group type: COMPARATOR
Intervention: Weight-for-length at enrolment
Number of subjects: 642
Study 28592289 — intervention group
Group type: COMPARATOR
Intervention: AD at two years
Number of subjects: 642
Study 28592289 — intervention group
Group type: COMPARATOR
Intervention: AD at any time
Number of subjects: 642
Study 28592297 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCA-negative at the time of switching to maintenance therapy
Number of subjects: 252
Study 28592297 — intervention group
Group type: COMPARATOR
Intervention: ANCA-positive at the time of switching to maintenance therapy
Number of subjects: 252
Study 28592313 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-initiated Kangaroo Mother Care (cKMC)
Number of subjects: 0
Study 28592319 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 360 μg of menaquinone-7 for 4 weeks
Number of subjects: 50
Study 28592319 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline dp-ucMGP levels
Number of subjects: 50
Study 28592387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (oral dabrafenib 150 mg twice per day and oral trametinib 2 mg once per day)
Number of subjects: 125
Study 28592387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 125
Study 28592387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 125
Study 28592387 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 125
Study 28592434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment for 2 years, starting at 5 mg once daily, uptitrated to 10 mg (age 6-<10 years) or 20 mg (age 10-<18 years).
Number of subjects: 197
Study 28592434 — intervention group
Group type: COMPARATOR
Intervention: Untreated unaffected siblings
Number of subjects: 197
Study 28592512 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal protein intake during pregnancy
Number of subjects: 0
Study 28592516 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal night-fasting interval
Number of subjects: 0
Study 28592516 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28592572 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron intervention (micronutrient powders containing vitamins and minerals with iron)
Number of subjects: 1943
Study 28592572 — intervention group
Group type: COMPARATOR
Intervention: No-iron group (control)
Number of subjects: 1943
Study 28592572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (combined analysis)
Number of subjects: 1943
Study 28592602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin responsiveness
Number of subjects: 0
Study 28592604 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of environmental enteropathy
Number of subjects: 0
Study 28592604 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28592612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried potato consumption
Number of subjects: 0
Study 28592616 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (6 mg/kg, administered intravenously every 2 weeks)
Number of subjects: 33
Study 28592616 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 33
Study 28592615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib and duligotuzumab combination
Number of subjects: 23
Study 28592615 — intervention group
Group type: EXPERIMENTAL
Intervention: Duligotuzumab
Number of subjects: 23
Study 28592615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Number of subjects: 23
Study 28592624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 150 mg/m2 via 8-hour intravenous infusion followed by gemcitabine
Number of subjects: 14
Study 28593306 — intervention group
Group type: EXPERIMENTAL
Intervention: Small nodal tumor infiltrates (SNTI)
Number of subjects: 122
Study 28593306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow micrometastases (BMM)
Number of subjects: 122
Study 28593306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined detection of BMM and SNTI
Number of subjects: 122
Study 28593789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer group
Number of subjects: 926
Study 28593789 — intervention group
Group type: COMPARATOR
Intervention: Non-cancer group
Number of subjects: 926
Study 28593789 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 926
Study 28593789 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
Number of subjects: 926
Study 28593789 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 926
Study 28593789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 926
Study 28593789 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors
Number of subjects: 926
Study 28594116 — intervention group
Group type: EXPERIMENTAL
Intervention: IgPro10
Number of subjects: 0
Study 28594116 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28594193 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported TBI
Number of subjects: 857
Study 28594193 — intervention group
Group type: EXPERIMENTAL
Intervention: History of multiple TBIs
Number of subjects: 857
Study 28594442 — intervention group
Group type: COMPARATOR
Intervention: BMI <20.32 kg/m² (lowest quartile)
Number of subjects: 29446
Study 28594442 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI quartiles (higher than 20.32 kg/m²)
Number of subjects: 29446
Study 28594711 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (16 weeks, repeated yearly for 3 years)
Number of subjects: 49
Study 28594711 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (second program, month 12-16)
Number of subjects: 49
Study 28594711 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (last program, month 24-28)
Number of subjects: 49
Study 28594711 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (control group)
Number of subjects: 49
Study 28594762 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention using a tablet computer-based decision aid for opioid prescribing after cesarean delivery.
Number of subjects: 51
Study 28594762 — intervention group
Group type: COMPARATOR
Intervention: Standard prescription of 40 tablets of 5 mg oxycodone.
Number of subjects: 51
Study 28595189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral BCAA (30.7 ± 1.1 g)
Number of subjects: 18
Study 28595189 — intervention group
Group type: COMPARATOR
Intervention: IV BCAA (30.7 ± 1.1 g)
Number of subjects: 18
Study 28595189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28595189 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BCAA tests
Number of subjects: 18
Study 28595298 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg once daily
Number of subjects: 16
Study 28595339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT-D)
Number of subjects: 133
Study 28595339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT-D) responders
Number of subjects: 133
Study 28595339 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 133
Study 28595616 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ridaforolimus 30 mg daily for 5 consecutive days per week combined with intravenous paclitaxel 175 mg/m2
Number of subjects: 24
Study 28595644 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-gene qRT-PCR panel
Number of subjects: 21
Study 28595644 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in gene expression
Number of subjects: 21
Study 28596770 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month booster regimen
Number of subjects: 12
Study 28596770 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month booster regimen
Number of subjects: 12
Study 28596794 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal therapy (5 shenwu capsules/administration, 3 times/day)
Number of subjects: 324
Study 28596794 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (placebo identical to donepezil tablets)
Number of subjects: 324
Study 28596794 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal therapy
Number of subjects: 324
Study 28596863 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents Make the Difference (PMD) intervention
Number of subjects: 270
Study 28596983 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G Procore needle using standard suction technique (SST)
Number of subjects: 60
Study 28596983 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G Procore needle using capillary suction technique (CST)
Number of subjects: 60
Study 28596983 — intervention group
Group type: COMPARATOR
Intervention: 25G needle (control)
Number of subjects: 60
Study 28597337 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain reward responses to food stimuli
Number of subjects: 32
Study 28597842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (initiated at 100 mg/day, uptitrated to 200, 300, or 400 mg/day over 12 weeks)
Number of subjects: 100
Study 28597967 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (200 mg IV loading dose on day 1, followed by 100 mg daily thereafter)
Number of subjects: 70
Study 28597967 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 70
Study 28598206 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-coated beads
Number of subjects: 0
Study 28598206 — intervention group
Group type: EXPERIMENTAL
Intervention: Human serum albumin-coated beads
Number of subjects: 0
Study 28598206 — intervention group
Group type: COMPARATOR
Intervention: Uncoated beads
Number of subjects: 0
Study 28598227 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention (PCI)
Number of subjects: 0
Study 28598227 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28598298 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive enteral nutrition (EEN) for 12 weeks
Number of subjects: 41
Study 28598554 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular cancer survivors
Number of subjects: 158
Study 28598554 — intervention group
Group type: COMPARATOR
Intervention: Biological brothers
Number of subjects: 158
Study 28598987 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian patients <60 years
Number of subjects: 1068318
Study 28598987 — intervention group
Group type: COMPARATOR
Intervention: White patients
Number of subjects: 1068318
Study 28598987 — intervention group
Group type: COMPARATOR
Intervention: Black patients
Number of subjects: 1068318
Study 28598987 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian patients
Number of subjects: 1068318
Study 28599608 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Function Index (BFI) derived from quantitative EEG (QEEG) features
Number of subjects: 720